Overview and Clinical Importance
Cardiovascular drugs form a cornerstone of veterinary therapeutics, used to manage congestive heart failure (CHF), arrhythmias, and hypertension across multiple species. Understanding these medications is essential for BCSE success, as they integrate pharmacology with clinical decision-making.
The BCSE tests your ability to select appropriate cardiovascular medications based on mechanism of action, species-specific considerations, and clinical scenarios. This domain accounts for 28-32 questions (combining pharmacology, physiology, and toxicology), making cardiovascular pharmacology a high-priority study area.
Positive Inotropes
Positive inotropes increase myocardial contractility, improving cardiac output in patients with systolic dysfunction. Two agents dominate veterinary cardiology: digoxin (a cardiac glycoside) and pimobendan (an inodilator).
Digoxin (Cardiac Glycoside)
Mechanism of Action
Digoxin inhibits the Na+/K+-ATPase pump on cardiac myocytes. This inhibition leads to:
- Increased intracellular sodium concentration
- Reduced Na+/Ca2+ exchanger activity (normally extrudes Ca2+ in exchange for Na+)
- Increased intracellular calcium, enhancing contractility (positive inotropy)
Additionally, digoxin has important vagomimetic effects, slowing AV nodal conduction. This makes it useful for rate control in atrial fibrillation.
MEMORY AID - "DIG Slows the Node"
Digoxin Inhibits the pump, Gathers calcium, and Slows AV node conduction. Remember: digoxin has a WEAK positive inotropic effect but STRONG vagomimetic (rate-slowing) effect.
Clinical Applications
- Rate control in supraventricular tachyarrhythmias (especially atrial fibrillation)
- Adjunctive therapy in dilated cardiomyopathy (DCM)
- Less commonly used as primary inotrope due to narrow therapeutic index
Pharmacokinetics and Dosing
MEMORY AID - Digoxin Toxicity Risk Factors: "HARD"
Hypokalemia, Age (geriatric), Renal disease, Drug interactions (quinidine, verapamil). Low potassium competes with digoxin at the Na+/K+-ATPase binding site, increasing digoxin binding and toxicity.
Pimobendan (Inodilator)
Mechanism of Action
Pimobendan is called an "inodilator" because it combines positive inotropic effects with vasodilation through two mechanisms:
1. Calcium Sensitization: Increases the sensitivity of cardiac troponin C to calcium, enhancing contractility WITHOUT increasing intracellular calcium or myocardial oxygen demand.
2. Phosphodiesterase III (PDE-III) Inhibition: Inhibits PDE-III in vascular smooth muscle and cardiac tissue, increasing cAMP. This causes vasodilation (decreased preload and afterload) and additional positive inotropy.
MEMORY AID - "PIMO = Pump IMprover with Open vessels"
Pimobendan: PDE-III Inhibition, Myocardial calcium sensitization, Opens vessels (vasodilation). Unlike digoxin, pimobendan does NOT increase myocardial oxygen demand.
Clinical Applications
- First-line therapy for CHF due to dilated cardiomyopathy (DCM)
- CHF due to myxomatous mitral valve disease (MMVD)
- Preclinical DCM in Doberman Pinschers and other at-risk breeds
- Stage B2 MMVD (cardiomegaly but no clinical signs) - per EPIC study
Pharmacokinetics and Dosing
MEMORY AID - Pimobendan Administration: "Empty for EPIC results"
Give pimobendan on an EMPTY stomach for best absorption. EPIC = Pimobendan started in stage B2 MMVD delays CHF onset.
Comparison: Digoxin vs. Pimobendan
[Include Image: Figure 1. Comparison of cardiac action potential effects of positive inotropes]
Source: https://commons.wikimedia.org/wiki/File:Cardiac_action_potential.svg
Antiarrhythmic Drugs
Antiarrhythmic drugs are classified using the Vaughan-Williams system based on their primary mechanism of action. Understanding this classification is essential for BCSE success.
[Include Image: Figure 2. Vaughan-Williams classification of antiarrhythmic drugs and their effects on the cardiac action potential]
Source: https://commons.wikimedia.org/wiki/Category:Cardiac_action_potentials
Vaughan-Williams Classification Overview
MEMORY AID - Vaughan-Williams Classes: "Some Block Potassium Channels"
Sodium (Class I), Beta-blockers (Class II), Potassium blockers (Class III), Calcium blockers (Class IV). Class I is further subdivided into IA, IB, IC based on effects on action potential duration.
Class I: Sodium Channel Blockers
Class IA: Quinidine and Procainamide
Mechanism: Block fast sodium channels with intermediate kinetics; also prolong repolarization (some K+ channel blockade). This prolongs both the QRS complex and QT interval.
Procainamide is the most commonly used Class IA agent in veterinary medicine. It is effective for both ventricular and supraventricular arrhythmias but has largely been superseded by Class III agents like sotalol.
Class IB: Lidocaine and Mexiletine
Mechanism: Block fast sodium channels with rapid onset-offset kinetics. Preferentially bind to inactivated (refractory) channels, making them most effective in ischemic or damaged tissue. They shorten action potential duration.
Lidocaine is the FIRST-LINE DRUG for acute ventricular arrhythmias in dogs. It has minimal hemodynamic effects and does not depress contractility, making it safe in CHF patients.
MEMORY AID - "Lidocaine LIVES in Ventricles"
Lidocaine is for LIFE-threatening VENTRICULAR arrhythmias only. It does NOT work on atrial arrhythmias. Remember: IV only, and watch for CNS toxicity (especially in cats!).
Mexiletine is an oral analogue of lidocaine used for chronic management of ventricular arrhythmias in dogs. It is often combined with a beta-blocker (atenolol) or sotalol for enhanced efficacy. Common in Boxers with arrhythmogenic right ventricular cardiomyopathy (ARVC).
Class II: Beta-Adrenergic Blockers
Mechanism: Block beta-adrenergic receptors, reducing sympathetic stimulation of the heart. This decreases heart rate (negative chronotropy), slows AV nodal conduction, and reduces myocardial oxygen demand.
MEMORY AID - Beta-Blocker Caution: "SLOW and WEAK"
Beta-blockers SLOW the heart and can make contraction WEAK. Avoid in active CHF; use with caution if systolic function is poor.
Class III: Potassium Channel Blockers
Mechanism: Block potassium channels, prolonging repolarization and the effective refractory period. This prolongs the QT interval on ECG.
Sotalol is the most commonly used Class III agent in veterinary medicine. It combines non-selective beta-blockade with K+ channel blockade, making it effective for both supraventricular and ventricular arrhythmias. It is particularly useful for Boxer dogs with ARVC.
Amiodarone has multiple mechanisms (Na+, K+, Ca2+ channel blockade + beta-blockade) but is rarely used in veterinary medicine due to significant side effects, including hepatotoxicity in dogs. Reserve for refractory arrhythmias.
Class IV: Calcium Channel Blockers
Mechanism: Block L-type calcium channels in cardiac tissue, particularly affecting the SA and AV nodes (which depend on calcium-mediated action potentials). This slows heart rate and AV conduction.
MEMORY AID - Calcium Channel Blocker Types: "A for Arteries, D for Dysrhythmias"
Amlodipine = Arteries (vasodilation for hypertension). Diltiazem = Dysrhythmias (heart rate control). Verapamil is rarely used due to negative inotropy.
Vasodilators
Vasodilators decrease vascular resistance, reducing cardiac workload. They are classified by their site of action: arteriolar (reduce afterload), venodilators (reduce preload), or mixed.
ACE Inhibitors
Mechanism: Angiotensin-Converting Enzyme (ACE) inhibitors block the conversion of angiotensin I to angiotensin II. This results in:
- Vasodilation (decreased angiotensin II-mediated vasoconstriction)
- Decreased aldosterone release (reduced sodium/water retention)
- Reduced sympathetic activation
- Decreased cardiac remodeling and fibrosis
[Include Image: Figure 3. Renin-Angiotensin-Aldosterone System (RAAS) and sites of drug action]
Source: https://commons.wikimedia.org/wiki/File:Renin-angiotensin-aldosterone_system.png
Common ACE Inhibitors in Veterinary Medicine
MEMORY AID - ACE Inhibitor Names: "All End in -PRIL"
Enalapril, Benazepril, Lisinopril, Ramipril - all ACE inhibitors end in -PRIL. Easy to identify on exams!
Clinical Applications
- Congestive heart failure (CHF) - part of standard "triple therapy"
- Proteinuric kidney disease (decreases glomerular capillary pressure)
- Systemic hypertension (second-line to amlodipine in cats)
- Myxomatous mitral valve disease (MMVD) and dilated cardiomyopathy (DCM)
Adverse Effects and Monitoring
- Hypotension (especially with concurrent diuretics)
- Azotemia (prerenal; due to decreased glomerular perfusion pressure)
- Hyperkalemia (rare when combined with loop diuretics)
- Monitor: BUN, creatinine, electrolytes, blood pressure
MEMORY AID - ACE Inhibitor Side Effects: "HAH"
Hypotension, Azotemia, Hyperkalemia. Monitor renal values and blood pressure when starting ACE inhibitors, especially in patients with pre-existing renal disease.
Other Vasodilators
Hydralazine
Mechanism: Direct arterial vasodilator (relaxes vascular smooth muscle). Reduces afterload only.
Hydralazine is a potent vasodilator used for acute CHF or refractory hypertension. It activates RAAS and can cause reflex tachycardia, so it should be combined with diuretics and/or beta-blockers.
Nitroprusside
Mechanism: Nitric oxide donor causing mixed venous and arterial vasodilation. Used IV for hypertensive emergencies.
Diuretics
Diuretics increase urine production by affecting ion transport in the nephron. They are essential for managing volume overload in CHF patients. Understanding their site of action is key for BCSE success.
[Include Image: Figure 4. Nephron anatomy showing sites of action of different diuretic classes]
Source: https://commons.wikimedia.org/wiki/Category:Diuretics (Renal Diuretics.gif or Diuretiques Nephron.png)
Loop Diuretics
Mechanism: Block the Na+/K+/2Cl- cotransporter (NKCC2) in the thick ascending limb of the loop of Henle. This inhibits reabsorption of approximately 25% of filtered sodium, producing a profound diuresis.
MEMORY AID - "Loops Lose Lots"
Loop diuretics (furosemide, torsemide) act on the Loop of Henle and cause the Largest diuresis. They also cause potassium Loss (hypokalemia).
Furosemide (Lasix)
Torsemide
Torsemide is a longer-acting loop diuretic with better oral bioavailability than furosemide. It may be useful in patients with furosemide resistance or for once-daily dosing (0.1-0.3 mg/kg PO q12-24h in dogs).
Adverse Effects of Loop Diuretics
- Hypokalemia (potassium wasting)
- Hyponatremia, hypochloremia (electrolyte depletion)
- Dehydration and prerenal azotemia
- RAAS activation (compensatory sodium/water retention)
- Ototoxicity (rare at standard doses; more common with IV bolus)
MEMORY AID - Loop Diuretic Side Effects: "CHALK"
Calcium loss (hypocalcemia possible), Hypokalemia, Alkalosis (metabolic), Loop activates RAAS, K+ wasting. Monitor electrolytes regularly!
Thiazide Diuretics
Mechanism: Block the Na+/Cl- cotransporter (NCC) in the distal convoluted tubule (DCT). Only ~5% of sodium is reabsorbed here, so thiazides are weaker diuretics than loop diuretics.
Hydrochlorothiazide and chlorothiazide are the most common examples. They are rarely used as monotherapy for CHF in veterinary medicine but are valuable in "sequential nephron blockade" when combined with loop diuretics.
MEMORY AID - Thiazide Site: "T for Thiazide, T for distal Tubule"
Thiazides work in the distal convoluted Tubule. They cause hypoKalemia but hyperCalcemia (opposite of loops for calcium).
Potassium-Sparing Diuretics
Site of action: Collecting tubule and late distal tubule
Spironolactone (Aldosterone Antagonist)
Mechanism: Competitive antagonist of aldosterone receptors in the collecting duct. Blocks aldosterone-mediated sodium reabsorption and potassium secretion.
Spironolactone is a WEAK diuretic but has important anti-remodeling and anti-fibrotic effects on the heart. This is its PRIMARY benefit in CHF management.
MEMORY AID - Spironolactone: "Spares Potassium, Stops Aldosterone"
Spironolactone is potassium-Sparing and Stops aldosterone. Give with food for better absorption (opposite of pimobendan!).
Comparison of Diuretics
MEMORY AID - Diuretic Sites: "PCT-Loop-DCT-CD"
Proximal Convoluted Tubule (carbonic anhydrase inhibitors), Loop of Henle (loop diuretics), Distal Convoluted Tubule (thiazides), Collecting Duct (K+-sparing). Follow the nephron!
Sequential Nephron Blockade
When loop diuretics alone are insufficient (diuretic resistance), adding diuretics that act at different nephron sites can enhance diuresis synergistically. This is called "sequential nephron blockade."
Example combination: Furosemide (loop) + Hydrochlorothiazide (DCT) + Spironolactone (collecting duct)